Moneycontrol PRO
Outskill Genai
HomeNewsBusinessStocksBiocon Biologics signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore

Biocon Biologics signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore

As part of the deal over 430 employees associated with the business are expected to transition to Eris

March 14, 2024 / 15:55 IST
As part of the deal over 430 employees associated with the business are expected to transition to Eris
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Biocon Biologics said that it has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.

    Biocon Biologics has signed a 10-year supply agreement with Eris, as a part of this deal. The transaction is expected to come into effect on April 1, 2024.

    The total transaction value of Rs 1242 crore which represents an accretive multiple of 3.4x of revenues and 18x of EBITDA. As part of the deal over 430 employees associated with the business are expected to transition to Eris.

    “This strategic collaboration with Eris Lifesciences for our portfolio of Metabolics, Oncology, and Critical Care products in India aligns with our commercial strategy to maximize patient reach and market potential,” said Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited in a press statement.

    “It builds on the success of our existing partnership with Eris for our Nephrology and Dermatology products and will allow us to deliver our high quality, lifesaving biosimilars to millions of patients in India,” he added.

    This collaboration is in line with Biocon Biologics’ strategy to unlock value from its legacy business of branded formulations built over the past two decades and extends its existing partnership with Eris for Biocon’s Nephrology and Dermatology business announced in Dec 2023, according to the company.

    The acquisition brings two major insulin brands – Basalog and Insugen – into the Eris fold. These are the largest Indian brands in
    their respective segments with market shares of over 10 percent. With this acquisition, Eris’s Diabetes care franchise will soon reach Rs 1,000 crore in revenue and become the 5th largest diabetes portfolio in India, according to the company. The deal will be funded through debt financing.

    Also read: Eris acquires nephrology, dermatology brands of Biocon for Rs 366 crore

     

    Neethi Rojan
    first published: Mar 14, 2024 03:45 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347